In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
about
Cooperativity in monomeric enzymes with single ligand-binding sitesMultiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites.Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosisPvdP is a tyrosinase that drives maturation of the pyoverdine chromophore in Pseudomonas aeruginosaSorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patientDimerization of human uridine diphosphate glucuronosyltransferase allozymes 1A1 and 1A9 alters their quercetin glucuronidation activitiesGlucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sitesLC-MS/MS quantification of sulfotransferases is better than conventional immunogenic methods in determining human liver SULT activities: implication in precision medicine.Species and gender differences affect the metabolism of emodin via glucuronidationUse of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin A by human liver and intestinal microsomes.Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones.Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.Albumin stimulates the activity of the human UDP-glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the effects are enzyme and substrate dependent.Metabolic pathways of the camptothecin analog AR-67Concurrent cooperativity and substrate inhibition in the epoxidation of carbamazepine by cytochrome P450 3A4 active site mutants inspired by molecular dynamics simulations.NMR-derived models of amidopyrine and its metabolites in complexes with rabbit cytochrome P450 2B4 reveal a structural mechanism of sequential N-dealkylationUDP-glucuronosyltransferase (UGT) 1A9-overexpressing HeLa cells is an appropriate tool to delineate the kinetic interplay between breast cancer resistance protein (BRCP) and UGT and to rapidly identify the glucuronide substrates of BCRP.A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1.CYP4F enzymes are the major enzymes in human liver microsomes that catalyze the O-demethylation of the antiparasitic prodrug DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime].Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4.CYP2E1 metabolism of styrene involves allostery.Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients.Gomisin A is a Novel Isoform-Specific Probe for the Selective Sensing of Human Cytochrome P450 3A4 in Liver Microsomes and Living Cells.Comparison of CYP3A4 and CYP3A5: the effects of cytochrome b5 and NADPH-cytochrome P450 reductase on testosterone hydroxylation activitiesStereoselective Glucuronidation of Bupropion Metabolites In Vitro and In VivoMeasuring specificity in multi-substrate/product systems as a tool to investigate selectivity in vivo.In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.Cooperative properties of cytochromes P450.Functional characterization of low-prevalence missense polymorphisms in the UDP-glucuronosyltransferase 1A9 gene.Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to HumanThe Promises of Quantitative Proteomics in Precision MedicineThe functional effects of physical interactions involving cytochromes P450: putative mechanisms of action and the extent of these effects in biological membranes.Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures.Farnesol is glucuronidated in human liver, kidney and intestine in vitro, and is a novel substrate for UGT2B7 and UGT1A1.Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of LapatinibGlucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes.Amplification of antioxidant activity of haptoglobin(2-2)-hemoglobin at pathologic temperature and presence of antibiotics.
P2860
Q27000989-D39A4166-0AE8-49C2-A394-2A4E7AF043F6Q27334876-99F5B3A9-EAFB-4F66-AEF9-EE96B0F6ACC3Q28367522-3FE2E76F-2CAC-4C59-A005-930B828F18AAQ28492673-1D10A221-5297-4C11-9BAE-4C83665D6D67Q28538514-22B7133F-4E81-48D7-87F8-02E383495E7CQ28834515-1808E499-EAF5-4132-BAF1-B234D938D94DQ33714571-28DBB4ED-4DB4-4183-99C3-5BF95B5FF376Q33818825-E5DAA43F-E7EB-4181-9754-5178013C329AQ33954631-606A3F8A-6526-4C91-9627-5D87A845BA8FQ33965411-FE67FE3F-1F54-4118-9C3D-CA9CCC56A103Q34138321-23CF8F4D-7896-481F-B99F-DA26A7B8CD1FQ34138998-501C409A-AF32-4767-B663-83FA02307F8DQ34185989-880B904D-499B-47A4-A608-15B67EFBF87EQ34571313-E56133A1-0993-48AA-B06B-F0B26E0FC038Q34715481-40F45E1C-578C-460D-8AD0-ECDB7C19F95CQ35027093-0D18FA83-DD97-4F77-A01D-B66B5E6F8E02Q35184715-4EC1E8E2-5B7C-4163-A83C-B7D60B3FD446Q35688457-07011989-9C7C-4605-AB1F-73110D5490A4Q35743429-E840974E-FA61-41F6-8B7A-858E847BF811Q35826926-C3215140-A9F7-4C32-9BC6-3ADC54442D65Q36115752-47ACF41B-1C7E-47D8-84C3-7BD18B9F78B0Q36143432-7958C0F6-B848-4DAC-9EA4-CE78C98E3EABQ36257083-0B546B62-FF02-4A73-8779-4E07C7AF40B8Q36296191-EA92E51A-2F9B-443A-93AA-96F478B82BC4Q36359764-669F1737-CFAD-4CE7-9BCD-ACFEA997D8B8Q36445096-5E307AD4-F7E0-494F-9397-9A5EE57E1048Q36700755-EB0F35E6-F4D5-438B-A24C-8F552217DC58Q36737009-FA15DAF0-6512-48C6-BDFB-A0F10F192780Q37046911-C13D0147-E2EF-4981-8502-8A643F23BDC1Q37237438-43BE6693-C1E3-4891-8070-29D7DB2ABBBBQ37366156-0C5F7B08-EF33-487A-93CD-F6BAA9904566Q37402758-05A9CE5B-F6FD-41E4-9CF7-3ECBCBACF84CQ37507317-F23A8FC0-9904-419D-97F7-49B2C2067996Q37647264-ED7B8F13-EB10-4501-8B67-F97C90A9DEB1Q38833525-62A94FB4-6808-405C-AC0D-DAD9EA582052Q38979533-70D825DE-83AB-4212-B664-B9232BC22B41Q40523859-7B127E65-1A94-4444-8A1B-29498EE33C98Q41640449-45FA6291-A7EF-4F42-BF31-FD42CC325C88Q41692521-7CF843DC-4BFD-43BD-BB3E-FB34E49E4F15Q42176407-5F86D504-E6F3-47B8-9483-BFF8049C832A
P2860
In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@ast
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@en
type
label
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@ast
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@en
prefLabel
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@ast
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@en
P1476
In vitro-in vivo scaling of CY ...... ssical Michaelis-Menten model.
@en
P2093
Houston JB
Kenworthy KE
P304
P577
2000-03-01T00:00:00Z